Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00732225 · ClinicalTrials.gov registry record · Phase 3
DisCoVisc Comparative Evaluation
A Phase 3 study of Cataracts, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 173
- Enrollment target
- 1
- Study location
NCT00732225 is a Phase 3 study of Cataracts that has completed, run by Alcon Research. The registered enrollment target is 173 participants, above the 76-participant average among 8 other Cataracts trials with a reported enrollment target (128% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00732225, a Phase 3 study of Cataracts, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 173 participants
- Enrollment target
- 1
- Study location
Study Summary
A comparison of the ability of DisCoVisc to that of other Opthalmic Viscosurgical Devices (OVDs) (DuoVisc®, BioVisc®, Healon5®, or Amvisc PLUS) regarding endothelial protection and anterior chamber space maintenance during non-eventful cataract surgery.
Conditions Studied
Interventions
- DEVICE DisCoVisc
- DEVICE DuoVisc
- DEVICE BioVisc
- DEVICE Healon5
- DEVICE Amvisc Plus
Study Locations (1)
Texas
- Alcon Call Center for Trial Locations - Fort Worth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 173 participants |
| Start Date | 2007-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00732225
The ClinicalTrials.gov registry entry for NCT00732225 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 173 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 76-participant average among 8 other Cataracts trials with a reported enrollment target (128% higher). The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cataracts appearing as the primary indexed condition, and to 5 interventions - of which DisCoVisc is the first listed.
NCT00732225 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00732225 about?
NCT00732225 is a clinical study titled "DisCoVisc Comparative Evaluation". A comparison of the ability of DisCoVisc to that of other Opthalmic Viscosurgical Devices (OVDs) (DuoVisc®, BioVisc®, Healon5®, or Amvisc PLUS) regarding endothelial protection and anterior chamber space maintenance during non-eventful cataract surgery.
What is the current status of trial NCT00732225?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 173 participants. The study started on 2007-05.
What conditions does trial NCT00732225 study?
This clinical trial studies the following conditions: Cataracts.
What interventions are being tested in trial NCT00732225?
The interventions under investigation include: DisCoVisc (DEVICE), DuoVisc (DEVICE), BioVisc (DEVICE), Healon5 (DEVICE), Amvisc Plus (DEVICE).
Who is sponsoring clinical trial NCT00732225?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00732225 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cataracts
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Intraocular Pressure Control Following One Site Versus Two Site Combined Phacoemulsification/IOL And Trabeculectomy
COMPLETED · NA
-
Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery
COMPLETED · Phase 4
-
Dispervise Ophthalmic Viscoelastic as an Agent to Ensure Watertight Wound Closure After Clear Corneal Cataract Incisions
COMPLETED · Phase 4
-
Clear Corneal Incisions and Arcuate Incisions Utilizing FemtoSecond Laser Technology for Cataract Surgery
COMPLETED · Phase 4
-
Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification
COMPLETED · Phase 4
-
A Post-Market Evaluation of LipiFlow Treatment in Cataract Surgery Practice
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.